Teleflex Plans $2.03B Divestiture, $1B Buybacks and 2026 EPS of $6.25–$6.55
Teleflex has agreed to sell its Acute Care, Interventional Urology and OEM divisions for $2.03 billion in cash, raising about $1.8 billion net after tax, with closings expected in H2 2026. It will deploy $1 billion to buy back shares and $800 million to reduce debt, while guiding 2026 adjusted EPS of $6.25–$6.55.
1. Major Portfolio Divestiture
Teleflex has executed definitive agreements to divest its Acute Care, Interventional Urology and OEM businesses for $2.03 billion in cash, generating approximately $1.8 billion net after tax. Transactions are slated to close in the second half of 2026, subject to customary regulatory approvals.
2. Capital Deployment Strategy
The company plans to allocate net proceeds with $1 billion earmarked for share repurchases and about $800 million for debt reduction, including roughly $700 million toward a deferred draw revolver. Management expects this capital redeployment to strengthen the balance sheet and enhance shareholder returns.
3. 2026 Financial Outlook
For fiscal 2026, Teleflex forecasts pro forma revenue growth of 4.5%–5.5% and adjusted EPS of $6.25–$6.55, while incurring approximately $90 million in separation-related stranded costs. The firm anticipates a steady-state adjusted operating margin of about 23% once transition services agreements are in place and will raise R&D spending to 8% of sales for the RemainCo.